Related Experiment Video
Updated: Sep 25, 2025
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
Published on: August 9, 2017
MicroRNAs as a Novel Player for Differentiation of Mesenchymal Stem Cells into Cardiomyocytes
Shirin Azizidoost1, Maryam Farzaneh2,3
1Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Insights
Mesenchymal stem cells (MSCs) offer a promising therapy for cardiovascular disease (CVD). MicroRNAs (miRNAs) are crucial regulators of MSCs differentiating into cardiomyocytes, advancing cardiac repair strategies.
Area of Science:
- Cardiovascular Biology
- Stem Cell Biology
- Molecular Medicine
Background:
- Cardiovascular disease (CVD) involves heart and blood vessel disorders.
- Limited cardiomyocyte proliferation hinders cardiac repair.
- Mesenchymal stem cells (MSCs) show potential for CVD therapy due to their differentiation capacity.
Approach:
- This review focuses on the role of microRNAs (miRNAs) in regulating MSC differentiation into cardiomyocytes.
- Investigates how miRNAs target key signaling pathways (STAT3, Wnt/β-catenin, Notch, TBX5) to influence cardiomyocyte development.
- Examines various in vitro and in vivo protocols for MSC-derived cardiomyocyte generation.
Key Points:
- MSCs can proliferate and differentiate into functional cardiomyocytes.
- MicroRNAs (miRNAs) are critical regulators of MSCs' cardiomyogenic differentiation.
- miRNAs modulate essential signaling pathways involved in cardiac development.
Conclusions:
- MicroRNAs are pivotal in directing MSC differentiation for potential CVD regenerative therapies.
- Understanding miRNA-mediated pathways can optimize strategies for generating MSC-derived cardiomyocytes.
- This research highlights miRNAs as key targets for enhancing cardiac repair in CVD.
Abstract:
Cardiovascular disease (CVD) is defined as a class of disorders affecting the heart and blood vessels. Cardiomyocytes and endothelial cells play important roles in cardiac regeneration and heart repair. However, the proliferating capacity of cardiomyocytes is limited. To overcome this issue, mesenchymal stem cells (MSCs) have emerged as an alternative strategy for CVD therapy. MSCs can proliferate and differentiate (or trans-differentiate) into cardiomyocytes. Several in vitro and in vivo differentiation protocols have been used to obtain MSCs-derived cardiomyocytes. It was recently investigated that microRNAs (miRNAs) by targeting several signaling pathways, including STAT3, Wnt/β-catenin, Notch, and TBX5, play a crucial role in regulating cardiomyocytes' differentiation of MSCs. In this review, we focused on the role of miRNAs in the differentiation of MSCs into cardiomyocytes.
